BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 26787231)

  • 1. Prognostic value of neutrophil-to-lymphocyte ratio in advanced oesophago-gastric cancer: exploratory analysis of the REAL-2 trial.
    Grenader T; Waddell T; Peckitt C; Oates J; Starling N; Cunningham D; Bridgewater J
    Ann Oncol; 2016 Apr; 27(4):687-92. PubMed ID: 26787231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capecitabine and oxaliplatin for advanced esophagogastric cancer.
    Cunningham D; Starling N; Rao S; Iveson T; Nicolson M; Coxon F; Middleton G; Daniel F; Oates J; Norman AR;
    N Engl J Med; 2008 Jan; 358(1):36-46. PubMed ID: 18172173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy.
    Lee S; Oh SY; Kim SH; Lee JH; Kim MC; Kim KH; Kim HJ
    BMC Cancer; 2013 Jul; 13():350. PubMed ID: 23876227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood neutrophil-lymphocyte ratio predicts survival in locally advanced cancer stomach treated with neoadjuvant chemotherapy FOLFOX 4.
    el Aziz LM
    Med Oncol; 2014 Dec; 31(12):311. PubMed ID: 25367855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group.
    Starling N; Rao S; Cunningham D; Iveson T; Nicolson M; Coxon F; Middleton G; Daniel F; Oates J; Norman AR
    J Clin Oncol; 2009 Aug; 27(23):3786-93. PubMed ID: 19398575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO.
    Dell'Aquila E; Cremolini C; Zeppola T; Lonardi S; Bergamo F; Masi G; Stellato M; Marmorino F; Schirripa M; Urbano F; Ronzoni M; Tomasello G; Zaniboni A; Racca P; Buonadonna A; Allegrini G; Fea E; Di Donato S; Chiara S; Tonini G; Tomcikova D; Boni L; Falcone A; Santini D
    Ann Oncol; 2018 Apr; 29(4):924-930. PubMed ID: 29324972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood neutrophil-lymphocyte ratio predicts survival for stages III-IV gastric cancer treated with neoadjuvant chemotherapy.
    Jin H; Zhang G; Liu X; Liu X; Chen C; Yu H; Huang X; Zhang Q; Yu J
    World J Surg Oncol; 2013 May; 11():112. PubMed ID: 23705622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral Venous Blood Platelet-to-Lymphocyte Ratio (PLR) for Predicting the Survival of Patients With Gastric Cancer Treated With SOX or XELOX Regimen Neoadjuvant Chemotherapy.
    Chen L; Hao Y; Cong X; Zou M; Li S; Zhu L; Song H; Xue Y
    Technol Cancer Res Treat; 2019 Jan; 18():1533033819829485. PubMed ID: 30760114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN study.
    Wood G; Grenader T; Nash S; Adams R; Kaplan R; Fisher D; Maughan T; Bridgewater J
    Anticancer Drugs; 2017 Jun; 28(5):546-550. PubMed ID: 28252533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival.
    Ota Y; Takahari D; Suzuki T; Osumi H; Nakayama I; Oki A; Wakatsuki T; Ichimura T; Ogura M; Shinozaki E; Suenaga M; Chin K; Yamaguchi K
    Cancer Chemother Pharmacol; 2020 Feb; 85(2):265-272. PubMed ID: 31907646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer.
    Okines AFC; Norman AR; McCloud P; Kang YK; Cunningham D
    Ann Oncol; 2009 Sep; 20(9):1529-1534. PubMed ID: 19474114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic value of the change in neutrophil-to-lymphocyte ratio during first-line palliative chemotherapy in patients with metastatic gastric cancer: A retrospective study.
    Bozkurt O; Firat ST; Dogan E; Cosar R; Inanc M; Ozkan M
    J BUON; 2019; 24(5):1992-1999. PubMed ID: 31786866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated Neutrophil-to-Lymphocyte Ratio Predicts Survival in Patients with Advanced Gastric Cancer Treated with Trastuzumab Combination Chemotherapy.
    Hwang GY; Baek DW; Cho HJ; Lee SJ; Chae YS; Kang BW; Lee IH; Kim JG; Seo AN; Bae HI; Park KB; Park JY; Kwon OK; Lee SS; Chung HY
    Anticancer Res; 2018 May; 38(5):3151-3156. PubMed ID: 29715156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in gastric cancer.
    Zhang Y; Lu JJ; Du YP; Feng CX; Wang LQ; Chen MB
    Medicine (Baltimore); 2018 Mar; 97(12):e0144. PubMed ID: 29561419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-treatment Peripheral Neutrophil-Lymphocyte Ratio as a Prognostic Marker in Gastric Cancer.
    Magdy M; Hussein T; Ezzat A; Gaballah A
    J Gastrointest Cancer; 2019 Dec; 50(4):763-768. PubMed ID: 30058031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab.
    Capone M; Giannarelli D; Mallardo D; Madonna G; Festino L; Grimaldi AM; Vanella V; Simeone E; Paone M; Palmieri G; Cavalcanti E; Caracò C; Ascierto PA
    J Immunother Cancer; 2018 Jul; 6(1):74. PubMed ID: 30012216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial.
    Ochenduszko S; Puskulluoglu M; Konopka K; Fijorek K; Urbanczyk K; Budzynski A; Matlok M; Lazar A; Sinczak-Kuta A; Pedziwiatr M; Krzemieniecki K
    Med Oncol; 2015 Oct; 32(10):242. PubMed ID: 26354521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral venous blood neutrophil-to-lymphocyte ratio predicts survival in patients with advanced gastric cancer treated with neoadjuvant chemotherapy.
    Chen L; Zuo Y; Zhu L; Zhang Y; Li S; Ma F; Han Y; Song H; Xue Y
    Onco Targets Ther; 2017; 10():2569-2580. PubMed ID: 28553122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combination of plasma fibrinogen and neutrophil lymphocyte ratio (F-NLR) is a predictive factor in patients with resectable non small cell lung cancer.
    Wang H; Zhao J; Zhang M; Han L; Wang M; Xingde L
    J Cell Physiol; 2018 May; 233(5):4216-4224. PubMed ID: 29057536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Derived neutrophil lymphocyte ratio is predictive of survival from intermittent therapy in advanced colorectal cancer: a post hoc analysis of the MRC COIN study.
    Grenader T; Nash S; Adams R; Kaplan R; Fisher D; Maughan T; Bridgewater J
    Br J Cancer; 2016 Mar; 114(6):612-5. PubMed ID: 26889974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.